Pfizer Protects $6.4 Billion Heart Disease Medication from Generics

Pfizer and Bristol Myers Squibb scored a significant legal win to protect Eliquis (apixaban), their $6.4 billion annual-revenue blood thinner, from generic competition. The U.S. District Court for the District of Delaware ruled the challenged patents valid, blocking generics from Sigmapharm, Sunshine Lake Pharma, Hec Pharm, and Unichem — all of which had received FDA approval years earlier but faced the patent barrier to market entry. Generic entry is now delayed until at least April 1, 2028, per Bristol Myers Squibb guidance, extending the brands' exclusivity well beyond the core compound patent expiration in November 2026.

Eliquis is the world's top-selling blood thinner and among the best-selling drugs globally, generating roughly $6.4 billion per year for the Pfizer-BMS partnership. The ruling preserves a critical revenue stream for PFE at a time when the company faces a well-documented patent cliff, with multiple blockbuster drugs losing exclusivity over the next several years. Secondary patents covering formulation and methods of use extend protection to June 2031, potentially pushing the generic market entry date even further.

The decision is a reminder of the complexity of pharmaceutical patent litigation: the FDA had approved generics as far back as 2019, but patent disputes have kept them off the market for years. For PFE investors, the ruling provides near-term revenue certainty, while payers and patient advocates continue to push for earlier generic access to one of the most widely prescribed anticoagulants. The 2028 generic entry date will be a significant overhang for Eliquis revenue in coming quarters.

Related Stocks

• PFE